On Might 15, 2026, FCPM III Companies B.V. reported a sale of 818,460 shares of Dyne Therapeutics (NASDAQ:DYN)an estimated $14.11 million commerce based mostly on quarterly common pricing.
What occurred
In accordance with a Securities and Exchange Commission (SEC) filing dated Might 15, 2026, FCPM III Companies B.V. decreased its place in Dyne Therapeutics by 818,460 shares. The estimated transaction worth was $14.11 million, calculated utilizing the imply unadjusted closing value for the primary quarter of 2026. The online place worth in Dyne Therapeutics shifted by $22.65 million over the interval, reflecting each buying and selling and value adjustments.
What else to know
-
This was a promote; Dyne Therapeutics now includes 11.8% of the fund’s 13F reportable AUM.
-
Prime holdings after the submitting:
-
NASDAQ: NAMS: $294.46 million (41.2% of AUM)
-
NASDAQ: DYN: $84.20 million (11.8% of AUM)
-
NASDAQ: BEFORE: $73.45 million (10.3% of AUM)
-
NASDAQ: ENGN: $65.60 million (9.2% of AUM)
-
NASDAQ: MPLT: $65.59 million (9.2% of AUM)
-
-
As of Might 14, 2026, Dyne Therapeutics shares had been priced at $18.28, up 56% over the previous yr and outperforming the S&P 500 by about 28 proportion factors.
Firm Overview
|
Metric |
Worth |
|---|---|
|
Market Capitalization |
$3.02 billion |
|
Internet Earnings (TTM) |
($451.71 million) |
|
Value (as of market shut Might 14, 2026) |
$18.28 |
Firm Snapshot
-
Dyne Therapeutics develops therapeutics for genetically pushed muscle illnesses, together with myotonic dystrophy kind 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, leveraging its proprietary FORCE platform.
-
The agency operates a biotechnology enterprise mannequin targeted on analysis and improvement of disease-modifying therapies, with income potential tied to future regulatory approvals and commercialization.
-
It targets sufferers with uncommon skeletal, cardiac, and metabolic muscle illnesses, primarily in the USA, with a concentrate on unmet medical wants within the neuromuscular illness phase.
Dyne Therapeutics is a biotechnology firm specializing within the improvement of therapeutics for uncommon, genetically pushed muscle illnesses. The corporate leverages its FORCE platform to advance a pipeline of disease-modifying candidates concentrating on important unmet wants in neuromuscular medication. Dyne’s technique facilities on innovation in focused supply and medical improvement to construct a aggressive edge within the muscle illness therapeutics market.
What this transaction means for buyers
Even after decreasing its place, FCPM nonetheless counts Dyne as its second-largest disclosed holding, representing practically 12% of reportable belongings. That is a fairly clear signal the fund hasn’t misplaced conviction, particularly with shares up practically 60% this previous yr.
The timing is fascinating as a result of Dyne has continued hitting main milestones. This week, the corporate submitted a Biologics License Utility to the FDA looking for accelerated approval for z-rostudirsen, its lead Duchenne muscular dystrophy remedy. Administration is concentrating on a possible U.S. launch within the first quarter of 2027 if approval and Precedence Assessment are granted.
The corporate additionally not too long ago launched the Section 3 FORZETTO research, a 72-week trial anticipated to enroll roughly 90 sufferers and function the confirmatory research for conventional approval. Chief Medical Officer Doug Kerr stated this system is designed to exhibit significant practical enhancements throughout mobility, lung well being, and patient-reported outcomes.
Past z-rostudirsen, the corporate is advancing further Duchenne candidates concentrating on a number of exon-skipping mutations and continues growing packages in myotonic dystrophy. For long-term buyers, the important thing query is execution. Regulatory approval could be transformative, however success will in the end rely on whether or not Dyne can translate promising medical knowledge right into a industrial franchise that extends past its lead program.
